Concepedia

Publication | Closed Access

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

DOI

372

Citations

25

References

2021

Year

Binghe Xu, Min Yan, Fei Ma, Xichun Hu, Jifeng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun,
The Lancet Oncology

References

YearCitations

Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

Dennis J. Slamon, William Godolphin, Lovell A. Jones,

Science

1989

6.8K

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks,

Journal of Clinical Oncology

2013

4K

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Sunil Verma, David Miles, Luca Gianni,

New England Journal of Medicine

2012

3.7K

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Charles E. Geyer, John Forster, Deborah Lindquist,

New England Journal of Medicine

2006

3.4K

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim,

New England Journal of Medicine

2011

2.5K

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

Sandra M. Swain, José Baselga, Sung‐Bae Kim,

New England Journal of Medicine

2015

2.1K

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Fátima Cardoso, A. Costa, Elżbieta Senkus,

Annals of Oncology

2016

2.1K

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K. Murthy, Sherene Loi, Alicia Okines,

New England Journal of Medicine

2019

1.3K

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

Fátima Cardoso, Elżbieta Senkus, A. Costa,

Annals of Oncology

2018

1.1K

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Sandra M. Swain, Sung‐Bae Kim, Javier Cortés,

The Lancet Oncology

2013

985

Page 1